Xilio Therapeutics
32 hedge funds and large institutions have $41.9M invested in Xilio Therapeutics in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 32 → 32 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.02% less ownership
Funds ownership: 4.18% → 4.16% (-0.02%)
18% less capital invested
Capital invested by funds: $51M → $41.9M (-$9.05M)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
+$36.2K |
| 2 |
Renaissance Technologies
New York
|
+$4.55K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$2.72K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$178K |
| 2 |
CC
Cannell Capital
Alta,
Wyoming
|
-$54K |
| 3 |
Millennium Management
New York
|
-$11.7K |
| 4 |
Morgan Stanley
New York
|
-$10.7K |
| 5 |
BlackRock
New York
|
-$5.45K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NL
26
NWAM LLC
Mercer Island,
Washington
| $26.2K | – | – | – |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $11.5K | -$596 | -14 | -4% |
|
28
JP Morgan Chase
New York
| $7.08K | – | – | – |
|
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | +$2.6K | +61 | +117% |
|
|
KFI
30
Key Financial Inc
West Chester,
Pennsylvania
| $2.17K | – | – | – |
|
31
UBS Group
Zurich,
Switzerland
| $527 | – | – | – |
|
32
Wells Fargo
San Francisco,
California
| $212 | – | – | – |
|
|
CC
33
Cannell Capital
Alta,
Wyoming
| – | -$54K | -1,216 | Closed |
|
XLO Hedge Fund Activity: Q2 2023 in Review
32 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q2 2023, worth a combined $41.9M — down 18% from $51M a quarter earlier.
Fund positioning in XLO was balanced in Q2 2023: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 6 trimmed.
The largest buyer was Charles Schwab, opening a new position worth an estimated $36.2K. The largest seller was Citadel Advisors, cutting an estimated $178K.
- 32 institutional investors held Xilio Therapeutics (XLO) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $41.9M of Xilio Therapeutics stock for Q2 2023, down 18% quarter-over-quarter.
- 1 fund opened new Xilio Therapeutics positions in Q2 2023 and 1 closed out, a net change of 0 holders.
- The largest Xilio Therapeutics buyer in Q2 2023 was Charles Schwab, an estimated $36.2K added.
- The largest Xilio Therapeutics seller in Q2 2023 was Citadel Advisors, an estimated $178K sold.
Based on aggregated 13F filings for Q2 2023.